Abstract
Extracorporeal life support (ECLS) has been increasingly used in the treatment of severe infarct-related cardiogenic shock in the last decade. The randomised ECLS-SHOCK trial demonstrated no benefit of early routine use on 30-day all-cause death. We herein present mid-term results. At 1-year follow-up, there were no significant differences in all-cause or cardiovascular mortality, neurologic outcome, recurrent myocardial infarction, repeat revascularisation and rehospitalisations for heart failure between ECLS and usual medical care.
Original language | English |
---|---|
Journal | European Heart Journal |
Volume | 45 |
Issue number | 39 |
Pages (from-to) | 4200-4203 |
Number of pages | 4 |
ISSN | 0195-668X |
Publication status | Published - 14.10.2024 |
Research Areas and Centers
- Research Area: Medical Genetics
- Centers: Cardiological Center Luebeck (UHZL)
DFG Research Classification Scheme
- 2.22-12 Cardiology, Angiology